Mylen Pharmaceuticals received permission from a federal district court in New Jersey to continue its antitrust lawsuit against Celgene Corporation.
The court found that there are sufficient facts for Mylen to plead an antitrust claim under Section 2 of the Sherman Act. Section 2 deals with end results that are anticompetitive, whereas Section 1 specifies and prohibits anti-competitive behavior. Mylen alleges that Celgene refused a generic rival access to samples of its branded drugs.
This case is one of few to deal with Section 2 in application to companies refusing to deal with a rival and, as such, is expected to be instructive.
Full Content: Health Law & Policy Matters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI